Pulmonary Hypertension in Patients with Chronic Kidney Disease on Dialysis and without Dialysis: Results of the PEPPER-Study

Stefan Pabst1, Christoph Hammerstingl1,3, Felix Hundt2,3, Thomas Gerhardt3, Christian Grohé4, Georg Nickenig1, Rainer Woitas2, Dirk Skowasch1*

1 The Department of Internal Medicine II – Cardiology/Pneumology, University of Bonn, Bonn, Germany, 2 The Department of Internal Medicine I - Nephrology, University of Bonn, Bonn, Germany, 3 Praxis für Nieren- und Hochdruckkrankheiten Bonn, Bonn, Germany, 4 The Lungenklinik Berlin-Buch, Berlin, Germany

Abstract

Pulmonary hypertension (PH) is common in patients with dialysis-dependent chronic kidney disease and is an independent predictor of mortality. However, specific hemodynamics of the pulmonary circulation, changes induced by hemodialysis and characterization into pre- or postcapillary PH have not been evaluated in patients with chronic kidney disease. We assessed consecutive patients with end-stage chronic kidney disease in WHO FC II with dyspnea unexplained by other causes on hemodialysis (group 1, n = 31) or without dialysis (group 2, n = 31) using right heart catheterization (RHC). In group 1, RHC was performed before and after dialysis. In end-stage chronic kidney disease, prevalence of precapillary PH was 13% (4/31), and postcapillary PH was discovered in 65% (20/31). All four cases of precapillary PH were unmasked after dialysis. In group 2, two cases of precapillary PH were detected (6%), and postcapillary PH was diagnosed in 22 cases (71%). This is the first study examining a large cohort of patients with chronic kidney disease invasively by RHC for the prevalence of PH. The prevalence of precapillary PH was 13% in patients with end-stage kidney disease. That suggests careful screening for precapillary PH in this selected patient population. RHC should be performed after hemodialysis.

Introduction

The prevalence of chronic kidney disease (CKD) in the developed world is 13% [1] and is recognized as a condition that elevates the risk of cardiovascular complications as well as kidney failure and other complications. End-stage kidney disease (ESKD) substantially increases the risk of death, cardiovascular disease, and use of specialized health care. In this context, pulmonary hypertension (PH) has been reported in patients with ESKD maintained on long-term hemodialysis. Based on echocardiographic studies, the prevalence of PH in these patient populations is estimated to be around 17–56% [2–7], and PH is an independent predictor of mortality in such patients [6,7]. However, these studies lack invasive hemodynamic data and thus cannot discriminate between pre- and postcapillary PH in unselected patients with or without symptoms.

PH is a hemodynamic and pathophysiologic state found in a range of clinical conditions and is characterized by an increase in mean pulmonary arterial pressure (mPAP) ≥25 mmHg; precapillary PH is defined by the additional criterion of a pulmonary arterial wedge pressure (PCWP) ≤15 mmHg [8]. The different forms of PH have been classified into five clinical groups with specific characteristics [8,9]. Group 1 consists of the major forms of pulmonary arterial hypertension (PAH: idiopathic, heritable and associated with connective tissue disease and congenital heart disease etc.). A diagnosis of PAH requires the exclusion of all other causes of PH, and specific treatments are available. Group 2 describes PH due to left heart disease including diastolic dysfunction, Group 3 PH due to lung diseases and/or hypoxia and Group 4 is chronic thromboembolic pulmonary hypertension (CTEPH). Group 5 consists of PH with unclear and/or multifactorial mechanisms including “chronic renal failure on dialysis” [8,9]. The pathogenesis of PAH is poorly understood, and the associated conditions that result in PAH are heterogeneous and seemingly unrelated.

The purpose of the PEPPER-study (“prevalence of precapillary pulmonary arterial hypertension in patients with end-stage renal disease”) was to assess the specific hemodynamics in CKD patients with otherwise unexplained dyspnea on hemodialysis and in those without dialysis, to elucidate possible risk factors contributing to PH, and to evaluate hemodynamic changes induced by hemodialysis – by use of right heart catheterization (RHC), the “gold standard” method for the diagnosis and characterization in pre- and postcapillary PH.
Methods

Patients
This was a prospective, single center study conducted at the University of Bonn, Germany. Local ethics committee approval was obtained prior to the inclusion of any patient in the study (Ethics committee, University of Bonn, Germany, 061/09) and the study was conducted according to the Declaration of Helsinki. Written informed consent was obtained from all participants involved in our study. Consecutive patients with severe CKD stage 4 or 5 [10] attending the clinic for regular treatment were assessed for enrollment suitability using defined inclusion and exclusion criteria. Within the one year ESKD patients with dialysis were recruited and compared to patients with CKD without dialysis. The study started in November 2009 and ended in October 2010 after 62 patients (31 patients in each group) were included. Detailed information is given in figure 1. Inclusion criteria were: adults $\geq 18$ years old, stage 4 or 5 CKD (defined as serum creatinine $\geq 200 \mu$mol/l [2.26 mg/dl] or glomerular filtration rate [$\text{GFR}$] $\leq 30$ ml/min/1.73 m$^2$ assessed by MDRD4-formula [11,12] for a time span $\geq 1$ year), on hemodialysis or without hemodialysis treatment, and in World Health Organization functional class (WHO FC) $\geq II$ with dyspnea unexplained by other causes. Exclusion criteria were: uncontrolled arterial hypertension (defined as mean blood pressure before entry into the study $\geq 160/100$ mmHg), current malignant diseases, pregnancy, left ventricular ejection fraction (LVEF) $<50\%$, mitral or aortic regurgitation $>\text{grade 2}$, aortic or mitral surface $<1.5$ cm$^2$, myocarditis, endocarditis, pericarditis, severe anemia (hemoglobin concentration $<10$ g/dl), severe chronic obstructive pulmonary disease (COPD) defined by FEV$_1$ $<60\%$ predicted, lung fibrosis, and known PAH medication with prostanoids, endothelin receptor antagonists, or phosphodiesterase-5 inhibitors. The following assessments were undertaken in all patients: medical history (including exact data concerning immunosuppressive medication, other medication and duration of renal insufficiency before starting dialysis and the time under dialysis as well as the daily amount of residual diuresis); clinical examination, including height, (dry-)weight, blood pressure; standard 12-lead-electrocardiography (ECG); transthoracic echocardiography (TTE); lung function testing (bodyplethysmography); laboratory investigations including blood count, and potassium, sodium, aspartate aminotransferase/alanine aminotransferase (AST/ALT), creatinine and urea levels.

Right heart catheterization
All patients underwent RHC. RHC in CKD patients on dialysis was performed before and after dialysis, if PH was confirmed with the first RHC. As shown in table 1 PH was defined as mean pulmonary arterial pressure (mPAP) $\geq 25$ mmHg regardless of the pulmonary capillary wedge pressure (PCWP). If mPAP was $\geq 25$ mmHg and PCWP was $\leq 15$ mmHg, the diagnosis of precapillary PH was made. In case of precapillary PH, a complete work-up (including chest computertomography-scan, ventilation-perfusion-scan, sleep apnea screening, ultrasound of the liver and laboratory testing) was performed to verify or exclude PAH. Vasoreactivity testing (inhaled iloprost 5 mg; iNeb, Philips Healthcare, Eindhoven, Netherlands) was performed in case of precapillary PH/PAH. Positive vasoreactivity was defined as a decrease of mPAP $\geq 10$ mmHg to reach $\leq 40$ mmHg with a stable cardiac index (CI) [8]. Cardiac index was measured by direct Fick method.

Statistical analysis
The German version of SPSS V17.0 (IBM, Munich, Germany) was used as a database and for statistical analysis. Data are expressed as mean $\pm$ standard deviation and as a percentage for categorial parameters. Differences between groups were compared with Student’s t-test and Mann-Witney-U test, as applicable. Chi-square test was used to estimate the occurrence of categorical parameters. Two-tailed bivariate correlations were determined by the Pearson’s coefficient. Statistical significance was set at $p<0.05$.

Figure 1. Enrolment of Patients. CKD: chronic kidney disease; Pulmonary hypertension (PH): mean pulmonary arterial pressure (mPAP) $\geq 25$ mmHg; *postcapillary PH: mPAP $\geq 25$ mmHg and pulmonary capillary wedge pressure (PCWP) $\geq 15$ mmHg; #precapillary PH: mPAP $\geq 25$ mmHg and PCWP $<15$ mmHg, +no PH: mPAP $<25$ mmHg.

doi:10.1371/journal.pone.0035310.g001
Results

Study population

From November 2009 to October 2010, consecutive patients with severe CKD stage 4 or 5 and in WHO FC ≥II with dyspnea unexplained by other causes were screened by transthoracic echocardiography (TTE) for study participation (Fig. 1).

In all, 62 patients met the inclusion criteria and agreed to participate in the study. The demographics and characteristics of the per-protocol population comprising 31 CKD patients on dialysis are shown in Table 1.

Table 1. Distinction of PH, precapillary PH and postcapillary PH [8].

| PH status         | mPAP <25 mmHg | mPAP ≥25 mmHg |
|-------------------|---------------|---------------|
| no PH             | n.a.          | n.a.          |
| precapillary PH   | mPAP ≥25 mmHg | mPAP ≥25 mmHg and PCWP <15 mmHg |
| postcapillary PH  | mPAP ≥25 mmHg and PCWP ≥15 mmHg |

Table 2. CHARACTERISTICS OF PEPPER PARTICIPANTS.

| Characteristics                        | Dialysis patients | Patients with CKD (serum creatinine ≥200 μmol/l) without dialysis | p-value |
|----------------------------------------|-------------------|-------------------------------------------------------------------|---------|
| Age at examination (yrs)               | 65.3±7.4          | 73.6±9.5                                                          | <0.001  |
| Gender (% female)                      | 35                | 48                                                                | 0.303   |
| BMI (kg/m^2)                           | 24.0±3.5 (post-dialysis) | 26.8±5.17                                                       | 0.015   |
| GFR (re-expressed MDRD ml/min)         | n.a.              | 21.9±4.37                                                        | n.a.    |
| CKD cause                              |                   |                                                                  |         |
| diabetes mellitus                      | 10 (32%)          | 13 (42%)                                                         | 0.430   |
| arterial hypertension                  | 4 (13%)           | 7 (23%)                                                          | 0.319   |
| Glomerulonephritis                     | 3 (10%)           | 5 (16%)                                                          | 0.449   |
| ADPKD                                  | 4 (13%)           | 0 (0%)                                                           | 0.039   |
| others (including unclear)             | 10 (32%)          | 6 (19%)                                                          | 0.246   |
| Median time to enrollment (years)      |                   |                                                                  |         |
| from first diagnosis of CKD            | 4.9±3.8           | 1.5±12.2                                                         | <0.001  |
| from first dialysis                    | 3.8±3.5           | n.a.                                                             | n.a.    |
| Comorbid conditions                    |                   |                                                                  |         |
| Cerebrovascular disease (CVD)          | 4 (13%)           | 8 (26%)                                                          | 0.199   |
| MI in medical history                  | 4 (13%)           | 6 (19%)                                                          | 0.490   |
| CAD                                    | 10 (32%)          | 13 (42%)                                                         | 0.430   |
| PCI                                    | 8 (26%)           | 10 (32%)                                                         | 0.258   |
| CABG                                   | 2 (7%)            | 3 (10%)                                                          | 0.416   |
| Neoplasm in medical history            | 2 (7%)            | 0 (0%)                                                           | 0.151   |
| PAD                                    | 4 (13%)           | 4 (13%)                                                          | 1.0     |
| Atrial fibrillation                    | 13 (42%)          | 19 (61%)                                                         | 0.127   |
| COPD (I–II)                            | 9 (29%)           | 9 (29%)                                                          | 1.0     |
| Diabetes mellitus                      | 12 (39%)          | 12 (39%)                                                         | 1.0     |
| Insulin use                            | 8 (26%)           | 8 (26%)                                                          | 1.0     |
| Arterial hypertension                  | 17 (55%)          | 19 (61%)                                                         | 0.203   |
| Smoking (actual and former)            | 19 (61%)          | 19 (61%)                                                         | 1.0     |
| Hyperlipidemia                         | 23 (75%)          | 24 (77%)                                                         | 0.767   |
| Medication                             |                   |                                                                  |         |
| Beta blockade                          | 21 (68%)          | 19 (61%)                                                         | 0.596   |
| Calcium channel blockade               | 11 (35%)          | 3 (10%)                                                          | 0.015   |
| ACE inhibitor                          | 13 (42%)          | 13 (42%)                                                         | 1.0     |
| AT-1 blockade                          | 4 (16%)           | 4 (13%)                                                          | 1.0     |
| Statin                                 | 23 (75%)          | 24 (77%)                                                         | 0.767   |
| Dyspnea WHO grade II/III/IV            | 22/7/2 (71%/23%/6%)| 19/10/2 (61%/32%/7%)                                             | 0.586   |

BMI: body mass index; GFR: glomerular filtration rate; CKD: chronic kidney disease; ADPKD: autosomal dominant polycystic kidney disease; MI: myocardial infarction; CAD: coronary artery disease; PCI: percutaneous coronary intervention; CABG: coronary artery bypass graft; PAD: peripheral artery disease; COPD: chronic obstructive pulmonary disease; AT-1: angiotensin 1.

doi:10.1371/journal.pone.0035310.t001
doi:10.1371/journal.pone.0035310.t002
### Table 3. HAEMODYNAMIC MEASUREMENTS IN TTE AND RHC.

|                      | All dialysis patients | Dialysis patients with PH | CKD patients without dialysis | p-value | p-value | p-value | p-value |
|----------------------|-----------------------|---------------------------|------------------------------|---------|---------|---------|---------|
|                      | before dialysis       | before dialysis           | after dialysis               | dialysis before vs. dialysis after | dialysis before vs. no dialysis | patients with PH: dialysis before vs. no dialysis | patients with PH: dialysis after vs. no dialysis |
|                      | n = 31                | n = 25                    | n = 25                       | n = 31  |         |         |         |
| TTE                  |                       |                           |                              |         |         |         |         |
| PAP systolic (mmHg)  | 43±16                 | 44±16                     | 37±13                        | <0.001  | 43±13   | 0.908   | 0.0679  | 0.122  |
| No. of patients PAP systolic ≥30 mmHg | 22 (71%)               | 18 (72%)                  | 15 (60%)                     | 0.370   | 24 (77%) | 0.562   | 0.642   | 0.159  |
| LVEF (%)             | 59±12                 | 61±12                     | 60±11                        | 0.870   | 56±6    | 0.170   | 0.057   | 0.121  |
| Pericardial effusion | 0                     | 0                         | 0                            | 1.0     | 1.0     | 1.0     | 1.0     |         |
| RHC                  |                       |                           |                              |         |         |         |         |
| PAP systolic (mmHg)  | 56±21                 | 62±18                     | 55±17                        | <0.001  | 52±15   | 0.324   | 0.019   | 0.456  |
| PAP diastolic (mmHg) | 27±13                 | 30±11                     | 26±10                        | <0.001  | 25±9    | 0.543   | 0.053   | 0.559  |
| PAP mean (mmHg)      | 38±15                 | 42±13                     | 36±12                        | <0.001  | 35±11   | 0.315   | 0.025   | 0.573  |
| PCWP (mmHg)          | 23±9                  | 25±8                      | 20±6                         | <0.001  | 22±8    | 0.917   | 0.263   | 0.255  |
| PH                   | 25 (81%)              | 25 (100%)                 | 24 (96%)                     | 0.327   | 24 (77%)| 0.755   | 0.011   | 0.048  |
| precapillary PH      | 0 (0%)                | 0 (0%)                    | 4 (16%)                      | 0.043   | 2 (6%)  | 0.151   | 0.196   | 0.251  |
| postcapillary PH     | 25 (81%)              | 25 (100%)                 | 20 (80%)                     | 0.012   | 22 (71%)| 0.374   | 0.003   | 0.438  |
| RAP (mmHg)           | 14±8                  | 13±9                      | 13±9                         | 1.0     | 13±6    | 0.788   | 0.167   | 0.167  |
| PVR (dyn · sec · cm⁻²)| 345±360               | 403±378                   | 400±398                      | 0.716   | 325±340 | 0.828   | 0.422   | 0.451  |
| CI (l/min/m²)        | 2.43±0.79             | 2.28±0.65                 | 2.28±0.76                    | 0.700   | 1.94±0.53| 0.005   | 0.033   | 0.028  |
| TPG (mmHg)           | 15±10                 | 18±10                     | 17±11                        | 0.142   | 12±9    | 0.227   | 0.057   | 0.079  |

CI: cardiac index; CKD: chronic kidney disease; serum creatinine ≥200 μmol/l; LVEF: left ventricular ejection fraction; PAP: pulmonary artery pressure; PCWP: pulmonary capillary wedge pressure; PH: pulmonary hypertension (PAP mean ≥25 mmHg); PVR: pulmonary vascular resistance; RAP: right arterial pressure; RHC: right heart catheterization; TTE: transthoracic echocardiography; TPG: transpulmonary gradient.
chronic hemodialysis treatment (group 1) and 31 patients with CKD (group 2) not on dialysis are presented in Table 2. We observed significant differences in age (the mean age of the dialysis cohort was 8 years lower than the nondialysis group), body mass index (BMI was lower in the dialysis group), median time to enrollment after manifestation of CKD (4.9 years in the dialysis group vs. 1.5 years in the non-dialysis group), and use of calcium channel blockers (increased in the dialysis group).

**Right heart catheterization**

All 62 patients underwent RHC; data are given in Table 3. In group 1, RHC was performed before and after dialysis, if mPAP was $\geq 25 \text{ mmHg}$ before dialysis (n = 25). If mPAP was determined as $< 25 \text{ mmHg}$ by RHC before dialysis, PH/PAH was excluded, and patients did not undergo a second RHC (n = 6). PH was observed in 25/31 (81%) patients in the dialysis group (before dialysis) versus 22/31 (71%) in the nondialysis cohort. After dialysis in group 1, prevalence of PH was 24/31 (77%, 20/31 postcapillary PH, 4/31 precapillary PH). There was a significant decrease of mPAP and PCWP after dialysis (mPAP from 62 $\pm$ 18 to 55 $\pm$ 17 mmHg; and PCWP from 25 $\pm$ 8 to 20 $\pm$ 6 mmHg). All four cases of precapillary PH were identified only by the RHC performed after dialysis treatment; none of the four patients was vasoactive to inhaled iloprost.

In nondialysis patients (group 2), postcapillary PH was diagnosed in 22/31 cases (71%); precapillary PH without vasoactivity was found in 2/31 cases (6%). Hemodynamic data were similar to the dialysis group (Table 3); only the higher CI in the dialysis group reached significance.

**Prevalence of precapillary and postcapillary PH**

The clinical and hemodynamic profiles of the patients with precapillary PH are displayed in Table 4. Further diagnostic workup according to clinical guidelines [8], including chest CT-scan, ventilation-perfusion-scan, sleep apnea screening, ultrasound of the liver and laboratory testing, confirmed precapillary PH due to hemodialysis (Dana Point Group 5 [9]) in three patients, and excluded PAH and diagnosed PH due to lung diseases and/or hypoxia in three further cases (Dana Point Group 3 [9]; two patients with mild PH and COPD, one patient with mild PH and sleep disordered breathing). In a total of 3/31 CKD patients on dialysis precapillary PH that was not explained by the PH workup (i.e. Dana Point group 1 or 5) was diagnosed, whereas precapillary PH (Dana Point group 1 or 5) was not found in nondialysis CKD patients. Thus, prevalence of precapillary PH (Dana Point group 1 or 5) was 10% in CKD patients on dialysis. There were no further clinically remarkable differences between the patients with precapillary compared to postcapillary PH or between patients with or without PH.

**Discussion**

We present the results of the first prospective study evaluating the prevalence of precapillary PH by use of RHC in a large cohort of patients with CKD on dialysis or without dialysis. In this symptomatic cohort with dyspnea WHO FC $\geq$II, the prevalence of precapillary PH (Dana Point group 1 or 5) was found to be 10% in the examined CKD patients requiring renal replacement therapy, whereas no cases of precapillary PH were detected in nondialysis CKD patients. In contrast, the prevalence of PH in CKD patients on or without dialysis was similar (77 vs. 71%, respectively) and considerably higher than previously reported [56 vs. 39% [3]; 44 vs. 32% [6]]. The reason for the higher prevalence in our study could be due to the high risk nature of our cohort.
which included only patients with dyspnea in WHO FC ≥II, whereas other studies also included asymptomatic patients [2–7]. Another strength of our study is the use of invasive methodology (RHC), considered a requirement and the “gold standard” for the differential diagnosis between pre- and postcapillary PH and assessment of hemodynamic impairment [8], for all study participants. Previous studies used only echocardiographic estimation of systolic PAP for PH diagnosis [2–7].

Since the prevalence of precapillary PH in our participants dramatically exceeds the prevalence of PAH in the general population of 15–50 per million adult population [8,10], end-stage kidney disease or dialysis itself may be a trigger for the development of precapillary PH in a predisposed patient, analogous to connective tissue disease, HIV, or portal hypertension. Hormonal and metabolic disturbances associated with CKD requiring dialysis might lead to pulmonary vascular constriction [8]. There are several pathogenetic mechanisms which may contribute to the development of precapillary PH in patients undergoing long-term dialysis, including impaired endothelial function [13], decreased bioavailability of nitric oxide (NO) [14,15], and increased levels of endothelin (ET)-1 [16–19]. PAP may also be increased by high cardiac output resulting from the arteriovenous access and/or concomitant renal anemia, as well as from fluid overload [9,20,21]. In addition, diastolic and systolic left heart dysfunctions are frequent in this setting [9] as also indicated by the high rate of postcapillary PH in this study. Due to the fact that we have excluded patients with reduced left ventricular ejection fraction the main diagnosis in our cohort probably is diastolic dysfunction.

In some patients, it may be difficult to distinguish between a diagnosis of precapillary PH and heart failure with preserved ejection fraction/diastolic dysfunction. In the present study, in CKD patients on dialysis, precapillary PH initially masked by fluid overload was unmasked by dialysis in 4/25 cases of primarily postcapillary PH. However, one may argue the opposite i.e. masking of postcapillary PH by fluid withdrawal. In particular, exercise hemodynamics or volume challenge have been proposed as means of identifying LV dysfunction, but these diagnostic tools require further standardization and can often not be applied to dialysis patients [8]. Even so, an elevated transpulmonary pressure gradient (TPG; mPAP minus PCWP) >12 mmHg is suggestive of intrinsic changes in the pulmonary circulation overriding the passive increase in PCWP. As demonstrated in Table 3, mPAP as well as PCWP were elevated before dialysis compared with afterwards, whereas TPG did not differ significantly. Moreover, in all CKD-precapillary-PH patients the stable “out-of-proportion” TPG suggests a precapillary component in addition to the fluid overload before dialysis. Therefore the elevated TPG might point towards CKD-precapillary-PH already at the time before hemodialysis. However, we propose that RHC should be performed after dialysis to unmask precapillary PH. The Dana Point classification assigns PH in patients with CKD to Group 5, i.e. all of the patients in the present study primarily belong into this group [8,9]. However, based on the present post-dialysis hemodynamics, a re-grouping of some CKD patients with precapillary PH into Group 1 at least is to be discussed in upcoming guidelines. Certainly there is need for more data, i.e. if histopathological changes of the here-described cohort are similar to those patients in Dana Point group 1 (PAH). We explicitly do not want to encourage CKD patients with a precapillary PH to be treated with specific PAH drugs, as there is no knowledge about the efficacy of those therapies in this cohort.

There are notable limitations of this single-center study. Each patient was only measured once invasively. Especially in the hemodialysis cohort it would be possible that RHC would have led to different results over the time caused by different fluid overload/dry weight. However, we think that our invasive approach is new and more catheterizations cannot be enforced in this patients’ cohort. We did not obtain data measuring extracellular fluid (ECF). Another limitation is the measurement of CI by direct Fick method. Due to arteriovenous fistula, the product of the Fick formula and therefore CI and PVR might be changed. However, there is no influence on PAP and PCWP.

Treatment regimens were not assessed. Therefore, the question how best to treat patients with CKD and PH/PAH remains unresolved. Although information on specific PAH treatment or clinical outcome would be of interest, it would necessitate a controlled, prospective study analyzing clinical end points with specific PAH treatment and requiring a follow-up period of several years and the recruitment of a large patient cohort. With the exception of isolated case reports [22], the efficacy of current medical therapeutics for PAH such as prostanooids, endothelin receptor antagonists and phosphodiesterase-5 inhibitors have not been studied in CKD patients.

In conclusion, this study provides evidence that precapillary PH is a common co-morbidity in CKD patients on dialysis. End-stage kidney disease and/or hemodialysis rather than the renal insufficiency itself seems to be the main determining risk factor for developing precapillary PH. Diagnostic RHC should be performed after dialysis to differentiate precapillary from postcapillary PH.

Acknowledgments

The authors thank Simone Kramér for excellent technical assistance.

Author Contributions

Conceived and designed the experiments: SP CG RW DS. Performed the experiments: SP FH RW DS. Analyzed the data: SP CH FH TG RW DS. Wrote the paper: SP CH FH TG CG GN RW DS.

References

1. Coree J, Selvin E, Stevens LA, Manzi J, Kusew JW, et al. (2007) Prevalence of chronic kidney disease in the United States. JAMA 298: 2038–2047.
2. Yigla M, Nakhoul F, Sabag A, Tov N, Gerevich B, et al. (2003) Pulmonary hypertension in patients with end-stage renal disease. Chest 123: 1577–1582.
3. Havlucu Y, Kursat S, Ekmekci C, Celik P, Setter S, et al. (2007) Pulmonary hypertension in patients with chronic renal failure. Respiration 74: 303–310.
4. Bozbas SS, Akcay S, Altin C, Bozbas H, Karacaoglu E, et al. (2009) Pulmonary hypertension in patients with end-stage renal disease undergoing renal transplantation. Transplant Proc 41: 2753–2756.
5. Ramaubh K, Deswal A, Herdejejen C, Aguilar D, Frost AE. A prospective echocardiographic evaluation of pulmonary hypertension in chronic hemodialysis patients in the United States: prevalence and clinical significance. Jt J Gen Med 2010:3: 279–286.
6. Abdelshah S, Elhinnawy S. Pulmonary hypertension in chronic renal failure patients. Am J Nephrol 2008:28: 996–997.
7. Yigla M, Fruchter O, Aharonson D, Yanay N, Reiner SA, et al. (2009) Pulmonary hypertension is an independent predictor of mortality in hemodialysis patients. Kidney Int 75: 969–975.
8. Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT), Galie N, Hoeper MM, Humbert M, Torbicki A, et al. (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 34: 1219–1263.
9. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, et al. (2009) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54: Suppl: S43–S54.
10. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, et al. (2006) Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 173: 1023–1030.
11. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification (2002) Am J Kidney Dis 39(suppl. 1): S1–S266.

12. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, et al. (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130: 461–470.

13. Thambryrajah J, Landray MJ, McGlynn FJ, Jones HJ, Wheeler DC, et al. (2000) Abnormalities of endothelial function in patients with pre-dialysis renal failure. Heart 83: 205–209.

14. Arese M, Strazy M, Ruva C, Costamagna G, Ghigo D, et al. (1995) Regulation of nitric oxide synthesis in uraemia. Nephrol Dial Transplant 10: 1386–1397.

15. Aznar-Salatti J, Escolar G, Cases A, Gomez-Ortiz G, Anton P, et al. (1995) Uraemic medium causes endothelial cell dysfunction characterized by an alteration of the properties of its subendothelial matrix. Nephrol Dial Transplant 10: 2199–2204.

16. Stefanidis I, Wurth P, Mertens PR, Ikononov V, Philippidis G, et al. (2004) Plasma endothelin-1 in hemodialysis treatment - the influence of hypertension. J Cardiovasc Pharmacol 44 Suppl 1: S43–S48.

17. Odetti P, Monacelli F, Storace D, Rahaudo C, Rossi S, et al. (2006) Correlation between pentosidine and endothelin-1 in subjects undergoing chronic hemodialysis. Horm Metab Res 38: 817–820.

18. Tomić M, Galesić K, Markota I (2008) Endothelin-1 and nitric oxide in patients on chronic hemodialysis. Ren Fail 30: 836–842.

19. El-Shafey EM, El-Nagar GF, Selim MF, El-Sorogy HA, Sahry AA (2008) Is there a role for endothelin-1 in the hemodynamic changes during hemodialysis? Clin Exp Nephrol 12: 370–375.

20. Nakhoud F, Yuça M, Gilman R, Reisner SA, Abassi Z (2005) The pathogenesis of pulmonary hypertension in haemodialysis patients via arterio-venous access. Nephrol Dial Transplant 20: 1686–1692.

21. Unal A, Tasdemir K, Oynam S, Duran M, Kocyigit I, et al. (2010) The long-term effects of arteriovenous fistula creation on the development of pulmonary hypertension in hemodialysis patients. Hemodial Int 14: 398–402.

22. Liefeldt L, van Giersbergen PLM, Dingemans J, Rudolph B, Walde T, et al. (2004) Treatment of secondary pulmonary hypertension with Bosentan and its pharmacokinetic monitoring in ESRD. Am J Kidney Dis 43: 921–926.